A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer

Brief description of study

The purpose of the study is to evaluate the safety and tolerability of BLU-945, an orally available, highly potent and selective inhibitor of EGFR resistance mutations, administered orally in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have previously received at least 1 prior EGFR-targeted TKI. We also want to determine the recommended Phase 2 dose of the study drug BLU-945. The study drug BLU-945 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s21-00117
ClinicalTrials.gov Identifier: NCT04862780
Principal Investigator: Elaine Shum.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.